Ep. 13: Edward Lanphier, chief editing officer
The recently retired founding CEO of Sangamo Therapeutics, Edward Lanphier, shares stories from two decades at the helm of the first biotech company to develop and take genome editing, using zinc finger nucleases, into the clinic.